WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 10, 612-623. Review Article ISSN 2277–7105

TOPICAL PRONIOSOMAL GEL: A COMPREHENSIVE REVIEW

Himanshu*[1] and Ashish Saini[2]

M. Pharmacy (Pharmaceutics), Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, 125001.

Article Received on
28 March 2025,

Revised on 18 April 2025,
Accepted on 08 May 2025

DOI: 10.20959/wjpr202510-36747

***Corresponding Author**
Himanshu
M. Pharmacy (Pharmaceutics), Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, 125001.

INTRODUCTION

Offering several benefits over conventional systemic drug delivery methods, topical medication administration has long been acknowledged as a successful way for delivering therapeutic substances straight to the site of action.[1] Among these advantages are avoidance of first-pass metabolism, better patient compliance, localised therapy with fewer overall adverse effects, and simplicity of use. But because of its unusual structure—tightly packed corneocytes buried in a lipid matrix the stratum corneum, the outermost layer of the skin, presents a significant barrier to effective medication absorption.[2] Many topical therapies are limited by this very strong biological barrier, which prevents most therapeutic molecules, especially those with a large molecular weight or hydrophilic character, from passing.[3] Developing new medication delivery methods has been a major focus to get past the restrictions of the skin barrier. Among them, vesicular systems like liposomes, niosomes, ethosomes, and transfersomes have demonstrated an amazing ability to improve medication penetration of the skin.[4] Particularly, niosomes, non-ionic surfactant-based vesicles, have attracted interest for their capacity to increase drug stability, provide focused drug administration, and encapsulate both hydrophilic and lipophilic pharmaceuticals. Although niosomal dispersions have advantages, their limited general use is hampered by stability problems, including aggregation, fusion, and drug leakage during storage.[5]

Proniosomal gels have become a creative and useful substitute to handle these stability issues. Dry, free-flowing compositions, proniosomal gels create niosomes when hydrated.[6] Usually, they consist of non-ionic surfactants, cholesterol, solvents like ethanol or isopropanol, and the medication of interest. Compared to standard niosomal suspensions, this special formulation

method provides enhanced physical stability, ease of handling, transportation, and shelf life. Applying the proniosomal gel to the skin causes it to absorb moisture, which generates niosomes in situ to improve medication absorption across the skin layers.[7]

Among its various appealing characteristics are regulated and prolonged drug release, great drug-loading capacity, and improved bioavailability in Proniosomal gels. They provide a flexible platform able to provide a wide spectrum of therapeutic compounds, including anti-inflammatory medications, antifungal agents, antibiotics, anticancer treatments, herbal extracts, and cosmetic actives. For the treatment of chronic skin disorders like psoriasis, fungal infections, acne, and pain management uses, their capacity to increase the penetration of poorly absorbed medications makes them very beneficial.[8]

Moreover, ongoing research on proniosomal technology has expanded its probable applications outside of dermatology to encompass systemically based transdermal medicine distribution.[9] Natural bioactive ingredients are increasingly being included in proniosomal gels in response to customer desire for biocompatible and "green" treatment choices. Furthermore, positioned to improve the therapeutic relevance of these systems are developments in stimuli-responsive proniosomal formulations and co-delivery techniques.[10]

In the realm of medication delivery, topical proniosomal gels are positioned as a major development given the increasing interest and progress in this sector. This paper attempts to give a thorough review of topical proniosomal gels together with their composition, mode of action, production methods, characterisation techniques, benefits, constraints, uses, and future directions.[11] Researchers, doctors, and pharmaceutical companies working to create efficient and patient-friendly topical treatments must first understand the ideas and concepts driving proniosomal gel technology.[12]

WHAT ARE PRONIOSOMAL GELS

In the realm of vesicular drug delivery methods, proniosomal gels show great development. These dry formulations create niosomes—bilayered vesicles able to encapsulate both hydrophilic and lipophilic medications—by hydration. These gels provide regulated release and enhanced permeability, therefore providing a quick way for medications to be delivered over the skin.[13] Proniosomal gels are based on the idea of stabilising niosomal dispersions, which during storage are generally prone to aggregation, fusion, and leakage. Proniosomal systems offer a neat solution to stability problems by converting the drug delivery form into a

dry, stable gel, therefore preserving the advantages of niosomal delivery.[14]



COMPOSITION OF PRONIOSOMAL GELS

Proniosomal gels consist essentially of non-ionic surfactants, cholesterol, solvents like ethanol or isopropanol, and the medication of interest. Once hydrated, non-ionic surfactants such as Span 60, Span 80, and Tween 80 are very important in producing the bilayered vesicles.[15] Usually used to improve membrane integrity and stiffness, cholesterol helps to lower medication leakage from the encapsulated form. Whereas water, either from the environment or supplied externally, causes the production of niosomes upon application to the skin, the solvents help to solubilise the surfactants and enable the gelation process. Proniosomal gels' special composition enables a variety of drugs, including lipophilic substances integrated into the lipid bilayer and hydrophilic molecules living in the aqueous core, to be encapsulated.[16]

MECHANISM OF ACTION

The way topical proniosomal gels work is that they create niosomes in situ upon application to the skin, therefore improving medication distribution throughout the stratum corneum. First made of non-ionic surfactants, cholesterol, and a solvent, which exist in a stable, dry, semi-solid state—proniosomal gels.[17] Applied to the skin, the inherent moisture on the surface hydrates the proniosomal gel, causing niosomal vesicles to develop spontaneously.[18]

These bilayered niosomes may contain lipophilic as well as hydrophilic medicines. Lipophilic

medications are included in the lipid bilayer; hydrophilic drugs are caught inside the watery core of the vesicles.[19] When first formed, the niosomes serve as carriers, allowing the medication to pass through the epidermal barrier. Several processes help to explain this increased permeation: surfactant fluidity of the stratum corneum lipids, disturbance of the tight lipid packing, and drug molecule vesicular movement.[20]

Once the niosomes reach the surface layers of the skin, they release the encapsulated medication in a regulated, steady flow. Maintaining effective medication concentrations at the site of action for long durations depends on this controlled release, which also helps to lower systemic absorption and side effects by lowering the frequency of injection. Furthermore, cholesterol in the vesicular bilayer improves niosome stiffness and stability, therefore guaranteeing maximum drug retention and release.[21]

Therefore, the proniosomal gel has two purposes: first, as a stable reservoir that changes into an effective vesicular system upon skin contact, and second, as a regulated delivery system that helps the therapeutic substances be released deliberately and continuously through and inside the skin.[22]

METHODS OF PREPARATION

Different techniques are used to prepare proniosomal gels; each has certain benefits. Dissolving the surfactant, cholesterol, and medication in an organic solvent, the coacervation phase separation technique then uses slow evaporation and addition of an aqueous phase to create a

gel.[23] Small-scale production makes extensive use of this straight forward approach. Using a slurry of the surfactant and medication with the low aqueous phase, another method—the slurry method—forms a gel with mild heating and agitation. Spray-coating techniques are also used in which surfactant-drug solutions are sprayed over a carrier ingredient, like maltodextrin, to generate a dry proniosomal powder that may be readily reconstituted into a gel as required. Each of these techniques seeks to guarantee homogeneous drug distribution, ideal vesicle size, and repeatability.[24]

CHARACTERIZATION OF PRONIOSOMAL GELS

The quality, durability, and efficacy of proniosomal gels depend on their characterization. First perceptions of homogeneity and aggregate presence come from visual examination. Usually falling between 5.5 and 7.0 to prevent irritation, the pH of the gel is tested to certify its suitability for the skin.[25] Determining the gel's spreadability and user comfort following application depends critically on viscosity measurements. The particle size and zeta potential of the niosomes produced upon hydration are found using advanced methods like dynamic light scattering (DLS). Better skin penetration often comes from smaller vesicles.[26] Another important factor impacting the therapeutic potential of the formulation is the entrapment efficiency, or proportion of medication contained within the vesicles. Whereas ex vivo skin permeation experiments employing animal or human skin assist in anticipating in vivo performance, in vitro drug release studies utilising dialysis membranes or Franz diffusion cells offer information on the release kinetics of the medication. Shelf life of the formulations is determined using stability experiments at several temperature and humidity levels.[27]

ADVANTAGES OF PRONIOSOMAL GELS

Over standard topical preparations and even over niosomal dispersions, proniosomal gels have numerous clear benefits. Their increased stability guarantees a longer shelf life free from appreciable physical or chemical change.[28] Proniosomal gels' dry nature makes handling, shipping, and storage simple. They improve patient compliance using regulated and continuous medication release, hence lowering the frequency of administration.[29] Proniosomal gels provide increased drug deposition at the target location with little systemic absorption by improving the penetration of pharmaceuticals through the stratum corneum, hence reducing adverse effects. Their adaptability as carriers for topical treatments comes from their capacity to capture a broad spectrum of medicines independent of their solubility characteristics.[30]

APPLICATIONS OF PRONIOSOMAL GELS

Proniosomal gels find extensive and varied uses, ranging from cosmetic to therapeutic ones for dermatological conditions. Proniosomal gels have been used in dermatology for treatments including psoriasis, fungal infections, and acne.[31] For example, in psoriasis models, methotrexate-loaded proniosomal gels have shown improved skin deposition and therapeutic effectiveness.[32] Likewise, proniosomal gels have been successfully used to transport antifungal drugs such as fluconazole and ketoconazole, therefore producing more antifungal activity than standard formulations. Antibiotics, including clindamycin phosphate, exhibit higher penetration into pilosebaceous units and enhanced antibacterial action when combined with proniosomal gels in the therapy of acne.[33]

Beyond its usage in dermatology, proniosomal gels have been used in pain management by directly delivering non-steroidal anti-inflammatory medicines (NSAIDs) such as diclofenac and ibuprofen straight to irritated tissues, therefore producing quicker relief with fewer gastrointestinal side effects.[34] Herbal extracts, including curcumin and aloe vera encapsulated in proniosomal gels, have demonstrated encouraging effects in the field of wound healing by speeding the healing process via their antioxidant and anti-inflammatory action. Retinol and coenzyme Q10 are anti-aging compounds delivered in cosmetics via proniosomal gels, therefore enhancing skin hydration, suppleness, and slowing of ageing process. Also effectively integrated into proniosomal systems are skin lightening treatments such as kojic acid, therefore improving their stability and effectiveness.[35]

RECENT ADVANCES AND INNOVATIONS

Recent developments in the sector have produced smart proniosomal gels that react to environmental stimuli, including pH or temperature, therefore improving the control over drug release. To get synergistic therapeutic benefits, co-delivery methods whereby two or more medications are encapsulated within the same proniosomal gel have been investigated.[36] Consumer tastes for "green" and biocompatible products are driving natural products and herbal extracts into proniosomal gels into increasing their popularity. Additionally, under investigation are emerging technologies like 3D printing for bespoke proniosomal gel patches with exact dose and improved patient comfort.[37]

LIMITATIONS AND CHALLENGES

Though they have many benefits, proniosomal gels have certain restrictions. Particularly in those with sensitive skin, several surfactants used in their composition might irritate skin or

induce allergic responses.[38] To produce consistent vesicle formation and drug encapsulation, the formulation procedure calls for exact optimisation of the surfactant-to-cholesterol ratio, solvent choice, and hydration conditions. Particularly in industrial manufacturing, where great batch consistency and cost-effectiveness are vital, scalability still presents a difficulty. The regulatory scene for proniosomal gels is still changing, and getting permission for new formulations calls for time-consuming and costly, rigorous toxicological, stability, and clinical research.[39]

REGULATORY ASPECTS

From a regulatory perspective, proniosomal gels meant for pharmaceutical use have to follow rules established by organisations as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).[40] These comprise thorough preclinical and clinical review, adherence to Good Manufacturing Practices (GMP), and stability tests under International Council for Harmonisation (ICH) criteria. Before the gels can be licensed for commercial use, their safety and effectiveness characteristics have to be fully verified by exhaustive in vitro, ex vivo, and in vivo research.[41]

FUTURE PERSPECTIVES

Looking ahead, proniosomal gels in topical medication delivery seem to have a bright and exciting future. Proniosomal gels catered to specific skin types, illness conditions, and treatment needs might be the trend towards personalised medicine.[42] One exciting method to improve medication administration across the skin barrier even further is the combination of microneedle arrays with proniosomal gels. Investigating biodegradable and biocompatible surfactants will probably help to solve issues of toxicity and skin irritation.[43] By use of artificial intelligence (AI) and machine learning in formulation design, component selection and prediction of formulation behaviour might be optimised, hence greatly reducing development timeframes. All things considered, proniosomal gels constitute a lively and fast-developing field of research and development with the potential to transform topical medication delivery.[44]

CONCLUSION

Table 1: Comparative Analysis of Topical Drug Delivery Systems.

Parameter	**Conventional Topical Gels**	**Liposomes**	**Niosomes**	**Proniosomal Gels**
Stability	Moderate	Low (prone to oxidation, leakage)	Moderate (aggregation, leakage)	High (dry form, reconstituted before use)
Drug Loading	Limited to hydrophilic drugs	oth hydrophilic and lipophilic	Both hydrophilic and lipophilic	Both hydrophilic and lipophilic
Penetration Efficiency	Moderate	Moderate to high	High	Very High
Ease of Storage	High	Low (requires refrigeration)	Moderate	High
Manufacturing Complexity	Low	High	High	Moderate
Controlled Release	Limited	Yes	Yes	Excellent (sustained release)
Shelf-life	Short to moderate	Short	Moderate	Long
arameter	**Conventional Topical Gels**	**Liposomes**	**Niosomes**	**Proniosomal Gels**
Patient Compliance	**Moderate**	**Moderate**	**Moderate**	**High (easy to use, fewer doses)**
Cost of Production	**Low**	**High**	**Moderate to high**	**Moderate**

In conclusion, topical proniosomal gels offer an innovative, efficient, and patient-friendly method of delivering a wide range of therapeutic agents directly to the skin or systemic circulation. Their unique composition and mechanism allow for enhanced stability, controlled release, improved drug bioavailability, and greater patient compliance. Although challenges remain in terms of formulation complexity, regulatory approval, and scalability, ongoing research and technological advancements continue to address these issues. Proniosomal gels thus stand as a testament to the progress made in the field of pharmaceutical technology, holding immense promise for the future of topical therapeutics.

REFERENCES

1. Govindarajan S, Manickam S, Nair SP, Sivagnanam S. A comprehensive study on pro-specific drug delivery system: Proniosomal gel. Indian Journal of Pharmaceutical Sciences [Internet], 2021; 84(1): Available from: http://dx.doi.org/10.36468/pharmaceutical-sciences.889
2. Parmar S, Tripathi S, Katiyar P, Kumar S, Bajpai P. Topical drug delivery system; proniosomal gel. Int J Appl Pharm., 2021; 13(1): 144–52.
3. Thilagam NB, Karthik VP, Gnanasambandan R, Sowmya C. A Comprehensive Review

of Strategies of Topical Niosomes and Their Synergistic Effect for Enhanced Therapeutic Outcomes. Pharmaceutical Nanotechnology. 2024.

4. Havelikar U, Sharma YS V, Rathee S GB, Singh GK, Sharma L G. A Comprehensive Review On Proniosomes: A New Concept In Ocular Drug Delivery. Int J Curr Pharm Res., 2023; 15(5): 1–9.
5. Khatoon M, Shah KU, Din FU, Shah SU, Rehman AU, Dilawar N, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv [Internet], 2017; 24(sup1): 56–69. Available from: http://dx.doi.org/10.1080/10717544.2017.1384520
6. Abdin N, Sahu BP, Rahman SS. A Review on Formulation and Evaluation of Nanoniosomal Topical gel of Paclitaxel for skin cancer. Research Journal of Pharmacy and Technology, 2022; 15(6): 2849–54.
7. Biradar SS. Formulation and Evaluation of Dithranol Proniosomal Gel (Master's thesis).
8. Lundie MM. Formulation and topical delivery of niosomes and proniosomes containing carnosine (Doctoral dissertation). Potchefstroom Campus;
9. Sharma RB, Kashyap D, Thakur H. Updated review on proniosomal transdermal drug delivery system. Int J Drug Dev Res J., 2023; 15(1).
10. Saharawat S, Verma S. A comprehensive review on niosomes as a strategy in targeted drug delivery: Pharmaceutical, and herbal cosmetic applications. Curr Drug Deliv [Internet]., 2024; 21(11): 1460–73. Available from: http://dx.doi.org/10.2174/0115672018269199231121055548
11. Pinzaru I, Tanase A, Enatescu V, Coricovac D, Bociort F, Marcovici I, et al. Proniosomal gel for topical delivery of rutin: Preparation, physicochemical characterization, and in vitro toxicological profile using 3D reconstructed human epidermis tissue and 2D cells. Antioxidants (Basel) [Internet]. 2021; 10(1): 85. Available from: http://dx.doi.org/10.3390/antiox10010085.
12. Pandit PG, Parakh DR, Patil MP. Proniosomal gel for improved transdermal drug delivery: an overview. World Journal of Pharmaceutical Research., 2015; 4(8): 560–86.
13. Ahmad MZ, Mohammed AA. Mokhtar Ibrahim M. Technology overview and drug delivery application of proniosome. Pharmaceutical development and technology., 2017; 22: 302–11.
14. Mishra A, Kapoor A, Bhargava S. Proniosomal gel as a carrier for improved transdermal drug-delivery. Asian J Pharm Clin Res., 2011; 2231.
15. Md S, Vasantakumar D, Hiremath D, Goudannavar P. Use of pronisome gel in

antidepressant therapy: design and evaluation. World Journal of Pharmaceutical Research., 2014; 3(4): 642–56.

16. Yadav K, Yadav D, Saroha K, Nanda S, Mathur P, Syan N. Proniosomal Gel: A novel approach for transdermal drug delivery. Der Pharmacia Lettre., 2010; 2(4): 189–98.
17. Eldeeb E, Salah A, Ghorab S. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Drug delivery, 2019; 26: 509–21.
18. Thomas L, Viswanad V. Formulation and optimization of clotrimazole-loaded proniosomal gel using 32 factorial design. Scientia pharmaceutica, 2012; 80(3).
19. Sankar V, Praveen C, Prasanth KG, Srinivas CR, Ruckmann K. Formulation and evaluation of a proniosome hydrocortisone gel in comparison with a commercial cream. Pharmazie., 2009; 64(11): 731–4.
20. Farooqui NA, Kar M, Singh RP, Jain S. Development of Proniosomal Gel: in- vitro, ex-vivo and in-vivo Characterization. Ind J Pharm Educ [Internet], 2017; 51(4): 758–64. Available from: http://dx.doi.org/10.5530/ijper.51.4.110
21. Mohamed LK, Abdelmottaleb M, Geneidi AS. Formulation and Characterization of Proniosomal Gels loaded with Levofloxacin for Dermal Drug Delivery. Archives of Pharmaceutical Sciences, Ain Shams University, 2021; 5: 288–303.
22. Vora B, Khopade AJ, Jain NK. Proniosome-based transdermal delivery of levonorgestrel for effective contraception. J Control Release [Internet], 1998; 54(2): 149–65. Available from: http://dx.doi.org/10.1016/s0168- 3659(97)00100-4
23. Mehta M, Garg M. Proniosomal gel: A promising drug carrier for boswellic acids. J Med Sci (Faisalabad, Pakistan) [Internet], 2015; 15(3): 130–4. Available from: http://dx.doi.org/10.3923/jms.2015.130.134
24. Rita B, Lakshmi PK. Preparation and evaluation of modified proniosomal gel for localised urticaria and optimisation by statistical method. Journal of Applied Pharmaceutical Science., 2012; 85–91.
25. Nimbalwar M, Upadhye K, Dixit G. Fabrication and evaluation of ritonavir proniosomal transdermal gel as a vesicular drug delivery system. Pharmacophore, 2016; 7(2–2016): 82–95.
26. Gupta S, Ahirwar D, Sharma NK, Jhade D. Proniosomal gel as a carrier for improved transdermal delivery of griseofulvin: preparation and in-vitro characterization. Research Journal of Pharmaceutical Dosage Forms and Technology, 2009; 1(1): 33–7.
27. Kute A, Goudanavar P, Hiremath D, Reddy SR. Development and characterization of

perindopril erbumine loaded proniosomal gel. Asian Journal of Pharmacy and Technology., 2012; 2(2): 54–8.

28. Ammar HO, Ghorab M, El-Nahhas SA. Higazy IM delivery of tenoxicam. International journal of pharmaceutics, 2011; 405: 142–52.
29. Mittal S, Chaudhary A, Chaudhary A, Kumar A. Proniosomes: the effective and efficient drug-carrier system. The Deliv [Internet], 2020; 11(2): 125–37. Available from: http://dx.doi.org/10.4155/tde-2019-0065
30. Sandeep G, Devireddy SR. Formulation and evaluation of fluconazole pro- niosomal gel for topical administration. Journal of Applied Pharmaceutical Science, 2014; 4(7): 98–104.
31. Shalaby R, Al-Sawahli MM, A. El-Telbany DF, Bahaa S, Hafed L, H. El- Ayouti S, et al. Optimization and clinical evaluation of hyaluronic acid proniosome loaded in situ gel for the management of recurrent aphthous stomatitis. J Drug Deliv Sci Technol [Internet]. 2024; 100(106067): 106067. Available from: http://dx.doi.org/10.1016/j.jddst.2024.106067
32. El-Emam GA, Girgis GNS, El-Sokkary MMA, El-Azeem Soliman OA, Abd El Gawad AEGH. Ocular inserts of voriconazole-loaded proniosomal gels: Formulation, evaluation, and microbiological studies. Int J Nanomedicine [Internet]. 2020; 15: 7825–40. Available from: http://dx.doi.org/10.2147/IJN.S268208
33. Pal P. Formulation development and evaluation of antifungal proniosomal gel for topical application. World J Pharm Res [Internet], 2017; 656–74. Available from: http://dx.doi.org/10.20959/wjpr20175-8300
34. Devi AS, Pinnika A, Divya P. Formulation and evaluation of candesartan cilexetil transdermal proniosomal gel. J Drug Del., 2014; 4(2): 90–8.
35. Sabareesh M, Khan PR, Sudheer B. Formulation and evaluation of lisinopril dihydrate transdermal proniosomal gels. Journal of Applied Pharmaceutical Science, 2011; 181–5.
36. Rehman K, Zulfakar MH. Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev Ind Pharm [Internet], 2014; 40(4): 433–40. Available from: http://dx.doi.org/10.3109/03639045.2013.828219
37. Muzzalupo R. Niosomes and proniosomes for enhanced skin delivery. Percutaneous Penetration Enhancers: Chemical Methods in Penetration Enhancement. Nanocarriers, 2016; 147–60.
38. Darson J, Thirunellai Seshadri R, Katariya K, Mohan M, Srinivas Kamath M, Etyala MA, et al. Design development and optimisation of multifunctional Doxorubicin-loaded

Indocyanine Green proniosomal gel derived niosomes for tumour management. Sci Rep [Internet], 2023; 13(1): 1697. Available from: http://dx.doi.org/10.1038/s41598-023-28891-8

39. Yasam VR, Jakki SL, Natarajan J, Kuppusamy G. A review on novel vesicular drug delivery: proniosomes. Drug Deliv [Internet], 2014; 21(4): 243–9. Available from: http://dx.doi.org/10.3109/10717544.2013.841783
40. Shah H, Nair AB, Shah J, Jacob S, Bharadia P, Haroun M. Proniosomal vesicles as an effective strategy to optimize naproxen transdermal delivery. J Drug Deliv Sci Technol [Internet], 2021; 63(102479): 102479. Available from: http://dx.doi.org/10.1016/j.jddst.2021.102479
41. Khindri S, Aggarwal G, Hari Kumar SL. Role of niosomes and proniosomes for enhancing bioavailability of drugs. J Drug Deliv Ther [Internet], 2015; 5(1). Available from: http://dx.doi.org/10.22270/jddt.v5i1.1043
42. Khatoon M, Sohail MF, Shahnaz G, Ur Rehman F, Fakhar-Ud-Din, Ur Rehman A, et al. Development and evaluation of optimized thiolated chitosan proniosomal gel containing duloxetine for intranasal delivery. AAPS PharmSciTech [Internet], 2019; 20(7): 288. Available from: http://dx.doi.org/10.1208/s12249-019-1484-y
43. Panchal PA, Patel S, Patel A, Ahlawat P. Proniosomes Nanoparticle for the treatment of peripheral arterial disease. Pharm Nanotechnol [Internet]. 2024; 12(5): 428–37. Available from: http://dx.doi.org/10.2174/2211738511666230912160729
44. Teaima MH, Gebril MI, Allah A, El-Nabarawi FI. Niosomes versus proniosomes as promising drug delivery systems in the treatment of diabetes mellitus. Int J App Pharm., 2022; 14(5): 32–40.